RxDoctor Payments Data

Mohammad Rezvani, MD

Internal Medicine · Los Angeles, CANPI 1487976668

Payments from drug & device makers

$631in general payments, 2019–2025

Across 29 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$324
  • Kowa Pharmaceuticals America, Inc.$162
  • Neurocrine Biosciences, Inc.$33
  • Teva Pharmaceuticals USA, Inc.$32
  • Lilly USA, LLC$28
  • Otsuka America Pharmaceutical, Inc.$22
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$631100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$631 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$741,007
Medicare patients
361
Services billed
5,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$76,422
EliquisApixaban184$68,503
TrulicityDulaglutide38$40,847
JanuviaSitagliptin Phosphate54$37,919
FarxigaDapagliflozin Propanediol36$36,438
OzempicSemaglutide19$24,256
XareltoRivaroxaban43$23,269
CreonLipase/Protease/Amylase16$20,791
BriviactBrivaracetam12$19,992
TradjentaLinagliptin54$19,802
XifaxanRifaximin20$19,438
SantylCollagenase Clostridium Hist.17$17,105
RexultiBrexpiprazole15$16,021
LinzessLinaclotide31$15,808
MyrbetriqMirabegron23$13,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Lumigan$324$41,96560 claims
Lilly USA, LLCTrulicity$28$40,84738 claims
Johnson & JohnsonXarelto$12$23,26943 claims
Otsuka America Pharmaceutical, Inc.Rexulti$22$16,02115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →